Tardive dyskinesia
Imagine a medication meant to help you, inadvertently causing a relentless, involuntary dance of your body. This is the reality of tardive dyskinesia—a neurological disorder where long-term drug use leads to repetitive, uncontrollable movements, often of the face and limbs. It's a challenging condition that highlights the delicate balance between therapeutic benefit and unexpected side effects, and its story is one of complex brain chemistry and a quest for better, safer treatments. Tardive dyskinesia is a medication-induced movement disorder, primarily caused by long-term use of dopamine-blocking drugs, particularly older antipsychotics. Its symptoms manifest as a wide range of involuntary movements, from subtle facial grimaces to severe, disabling contortions of the limbs and torso, profoundly impacting daily life. Understanding its causes, identifying risk factors, and developing targeted treatments are crucial steps toward mitigating this often irreversible condition and improving patient outcomes.
AI Summary
Imagine a medication meant to help you, inadvertently causing a relentless, involuntary dance of your body. This is the reality of tardive dyskinesia—a neurological disorder where long-term drug use leads to repetitive, uncontrollable movements, often of the face and limbs. It's a challenging condition that highlights the delicate balance between therapeutic benefit and unexpected side effects, and its story is one of complex brain chemistry and a quest for better, safer treatments.
- Tardive dyskinesia is a medication-induced movement disorder, primarily caused by long-term use of dopamine-blocking drugs, particularly older antipsychotics.
- Its symptoms manifest as a wide range of involuntary movements, from subtle facial grimaces to severe, disabling contortions of the limbs and torso, profoundly impacting daily life.
- Understanding its causes, identifying risk factors, and developing targeted treatments are crucial steps toward mitigating this often irreversible condition and improving patient outcomes.
The Unwanted Dance: What is Tardive Dyskinesia?
Tardive dyskinesia, or TD, is a perplexing neurological disorder that literally means 'late-appearing abnormal movement.' It's an iatrogenic condition, meaning it's caused by medical treatment—specifically, the long-term use of certain medications. This can lead to a variety of repetitive, involuntary body movements, profoundly impacting a person's life.
The Root Cause: Dopamine Blockers
The primary culprits behind TD are medications that block dopamine receptors in the brain. These include antipsychotics, often used to treat mental illnesses like schizophrenia, as well as some drugs for gastrointestinal or neurological problems, like metoclopramide. The 'tardive' part refers to its typical onset—not immediately, but usually after months or even years of consistent use.
Unpacking the 'Why': Dopamine Hypersensitivity
While the exact mechanism is still a subject of intense research, a leading theory points to 'dopamine supersensitivity.' Imagine your brain's dopamine receptors—particularly the D2 receptors—becoming overly sensitive because they've been blocked for so long by medication. When the drug effects fluctuate, or even if the dosage changes, these hypersensitive receptors can essentially 'overreact,' leading to the involuntary movements.
It's not just about receptor sensitivity, though. Other factors like oxidative stress in the brain, genetic predispositions, and even a person's overall brain health play a role. These elements can make some individuals more vulnerable to developing TD, even when taking similar doses of the same medication.
The type of medication also matters. Older, or 'typical,' antipsychotics are associated with a higher risk of TD—around 30%. Newer 'atypical' antipsychotics generally have a lower risk, closer to 20%, but they are by no means entirely free from causing this challenging condition.
The Spectrum of Involuntary Movements
The hallmark of tardive dyskinesia is its repetitive, involuntary movements. These aren't intentional; they're an unwelcome guest in the body's control system. The movements can be quite varied, often starting subtly and progressing over time.
Many of these movements are concentrated in the face. Picture grimacing, sticking out the tongue, smacking or puckering the lips, or excessive blinking. These facial tics can be constant and difficult to control, making social interactions particularly challenging for those affected.
But TD isn't limited to the face. Rapid, involuntary movements can also affect the limbs, torso, and fingers. In severe cases, legs might be so impacted that walking becomes incredibly difficult or even impossible. It's a striking contrast to Parkinson's disease, where people struggle to initiate movement; with TD, the struggle is often to stop moving.
Beyond visible movements, some individuals might experience less common but equally distressing symptoms, such as respiratory irregularities. This can manifest as grunting or difficulty breathing, adding another layer of complexity to an already challenging condition, though these cases are thankfully rarer.
The Danger of Misdiagnosis
One of the most tragic aspects of tardive dyskinesia is its potential for misdiagnosis. Sometimes, the involuntary movements are mistakenly attributed to the underlying mental illness itself, rather than being recognized as a medication side effect. This can lead to a dangerous cycle.
When misdiagnosed, patients might be prescribed even more antipsychotic medication, unknowingly exacerbating their TD. This can lead to a more severe and disabling case, tragically shortening the typical survival period for those already grappling with serious health issues.
Related 'Tardive' Conditions
TD isn't alone in the family of 'tardive' disorders. There are closely related conditions, also typically arising from long-term medication use, that present slightly differently. Tardive dystonia involves sustained muscle contractions leading to twisting, repetitive movements or abnormal postures.
Then there's tardive akathisia, characterized by an intense feeling of inner tension, restlessness, and an irresistible urge to move. It's an agonizing sensation, often compelling individuals to constantly shift, pace, or fidget. Tardive tourettism presents with tics similar to Tourette syndrome, and tardive myoclonus involves brief, lightning-fast muscle jerks.
Monitoring and Diagnosis
Diagnosing TD primarily involves careful clinical observation of the patient's movements. Clinicians look for tell-tale signs like facial grimacing, lip smacking, or unusual limb movements. The process usually involves ruling out other potential causes for these involuntary movements.
A key tool in monitoring symptoms, particularly when psychotropic medications are prescribed, is the Abnormal Involuntary Movement Scale, or AIMS examination. This isn't a diagnostic test in itself, but rather a standardized way to assess and scale the severity of involuntary movements in the face, trunk, and limbs. Consistent AIMS evaluations over time can help track the progression of TD and inform treatment decisions.
Prevention Strategies
Preventing TD is paramount. The core strategy involves using the lowest effective dose of an antipsychotic medication for the shortest possible duration. However, this must be carefully balanced with the need to prevent recurrence of serious psychiatric conditions like psychosis, which often require long-term treatment.
When medication is necessary, choosing 'atypical' antipsychotics over 'typical' ones is often recommended, as they carry a lower risk of TD. Researchers are also exploring potential preventative measures, including high-dose vitamins and antioxidants like Vitamin E, though more definitive evidence is still needed.
Treatment Approaches
If TD is diagnosed, the first step is often to discontinue the causative drug, if medically feasible, or switch to a lower-risk alternative like clozapine. It's important to note, however, that stopping the medication might temporarily worsen symptoms before any improvement is seen, and symptoms can unfortunately persist for months, years, or even permanently.
In recent years, new targeted treatments have emerged. Valbenazine and deutetrabenazine, both FDA-approved, work by reducing the amount of dopamine released in certain brain areas, helping to lessen the involuntary movements. These represent significant advancements in managing TD symptoms.
Other treatments include tetrabenazine, another dopamine-depleting drug, and botulinum toxin injections for specific, focal dystonias. While some approaches like high-dose Vitamin B6 or clonidine show promise, the evidence for many other historical treatments, like benzodiazepines, remains insufficient.
The Global Impact of TD
Tardive dyskinesia is a significant public health concern, particularly among individuals requiring long-term psychiatric care. Estimates suggest that around 30% of people on typical antipsychotics may develop TD, with rates around 20% for those on atypical medications. Longitudinal studies show that for older populations, the risk can climb dramatically, with a majority developing the disorder after several years.
Certain demographics are at higher risk. Older individuals, especially elderly women, are more susceptible. Other risk factors include a history of mood disorders, organic brain injuries, diabetes, and even smoking. These factors highlight the complex interplay of biology, lifestyle, and medication in the development of TD.
Beyond the physical movements, TD carries a heavy social and psychological toll. The visible nature of the symptoms can lead to social isolation, increased risk of body dysmorphic disorder, and, tragically, even suicide. Emotional or physical stress can intensify the movements, underscoring the profound impact on a person's overall well-being.
TD in Popular Culture
While not frequently portrayed, tardive dyskinesia has made appearances in media, helping to raise awareness. A notable example is Michael J. Fox, who himself lives with Parkinson's disease, portraying a lawyer with tardive dyskinesia in the TV series 'The Good Wife' and 'The Good Fight.' These portrayals offer a glimpse into the daily challenges faced by those living with this condition.
Article
Tardive dyskinesia
Tardive dyskinesia (TD) is an iatrogenic disorder that results in involuntary repetitive body movements, which may include grimacing, sticking out the tongue or smacking the lips, which occurs following treatment with medication. Additional motor symptoms include chorea or athetosis. In about 20% of people with TD, the disorder interferes with daily functioning. If TD is present in the setting of a long-term drug therapy, reversibility can be determined primarily by severity of symptoms and how long symptoms have been present before the long-term drug has been stopped.
Tardive dyskinesia occurs as a result of long-term use of dopamine-receptor-blocking medications such as antipsychotics and metoclopramide. These medications are usually used for mental illness but may also be given for gastrointestinal or neurological problems. The condition typically develops only after months to years of use. The diagnosis is based on the symptoms after ruling out other potential causes.
Efforts to prevent the condition include either using the lowest possible dose or discontinuing use of antipsychotics. Treatment includes stopping the antipsychotic medication if possible (although this may temporarily worsen symptoms) or switching to clozapine. Other medications such as valbenazine, tetrabenazine, or botulinum toxin may be used to lessen the symptoms. With treatment, some see a resolution of symptoms, while others do not.
Rates in those on atypical antipsychotics are about 20%, while those on typical antipsychotics have rates of about 30%. The risk of acquiring the condition is greater in older people, for women, as well as patients with mood disorders and/or medical diagnoses receiving antipsychotic medications. The term tardive dyskinesia first came into use in 1964.
Signs and symptoms
Tardive dyskinesia
Tardive dyskinesia is characterized by repetitive, involuntary movements, which occurs following treatment with medication (hence the term tardive). Some examples of these types of involuntary movements include:
• Grimacing • Tongue movements • Lip smacking • Lip puckering • Pursing of the lips • Excessive eye blinking • Rapid, involuntary movements of the limbs, torso, and fingers may also occur.
In some cases, an individual's legs can be so affected that walking becomes difficult or impossible. These symptoms are the opposite of those present in people diagnosed with Parkinson's disease. People with Parkinson's have difficulty moving, whereas people with tardive dyskinesia have difficulty not moving.
Respiratory irregularity, such as grunting and difficulty breathing, is another symptom associated with tardive dyskinesia, although studies have shown that the rate of people affected is relatively low.
Tardive dyskinesia is often misdiagnosed as a mental illness rather than a neurological disorder, and as a result, people are prescribed Antipsychotic drugs, which increase the probability that the person will develop a severe and disabling case, and shortening the typical survival period.
Other closely related neurological disorders have been recognized as variants of tardive dyskinesia. Tardive dystonia is similar to standard dystonia but permanent. Tardive akathisia involves painful feelings of inner tension and anxiety and a compulsive drive to move the body. In some extreme cases, afflicted individuals experience so much internal tension that they lose their ability to sit still. Tardive tourettism is a tic disorder featuring the same symptoms as Tourette syndrome. The two disorders are extremely close in nature and often can only be differentiated by the details of their respective onsets. Tardive myoclonus, a rare disorder, presents as brief jerks of muscles in the face, neck, trunk, and extremities.
"AIMS Examination": This test is used when psychotropic medications have been prescribed because people sometimes develop tardive dyskinesia due to prolonged use of antipsychotic medications. The Abnormal Involuntary Movement Scale (AIMS) examination is a test used to identify the symptoms of tardive dyskinesia (TD). The test is not meant to tell whether there is an absence or presence of tardive dyskinesia. It just scales to the level of symptoms indicated by the actions observed. The levels range from none to severe. The AIMS examination was constructed in the 1970s to measure involuntary facial, trunk, and limb movements. It is best to do this test before and after the administration of the psychotropic drugs. Taking the AIMS consistently can help to track severity of TD over time.
Causes
Tardive dyskinesia
Tardive dyskinesia was first described in the 1950s shortly after the introduction of chlorpromazine and other antipsychotic drugs. However, the exact mechanism of the disorder remains uncertain. One line of evidence suggests that tardive dyskinesia may result primarily from antipsychotic dopamine supersensitivity in the nigrostriatal pathway, with the D2 dopamine receptor being most affected. Antipsychotics act primarily on this dopamine system, and older antipsychotics, which have greater affinity for the D2 binding site, are associated with high risk for tardive dyskinesia. The D2 hypersensitivity hypothesis is also supported by evidence of a dose–response relationship, withdrawal effects, studies on D2 agonists and antagonists, animal studies, and genetic polymorphism research. However, the time-course of tardive dyskinesia and its increased prevalence in older populations and drug and alcohol users suggest that dopamine supersensitivity is not a complete explanation. Oxidative stress is another causal explanation that accounts for the deficits in the dopamine supersensitivity hypothesis.
Given similar doses of the same antipsychotic, differences among individuals still exist in the likelihood of developing tardive dyskinesia. Such individual differences may be due to genetic polymorphisms, which code for D2 receptor binding site affinity, or prior exposure to environmental toxins. Decreased functional reserve or cognitive dysfunction, associated with aging, intellectual disability, alcohol and drug use, or traumatic head injuries, has also been shown to increase risk of developing the disorder among those treated with antipsychotics. Antipsychotic drugs can sometimes camouflage the signs of tardive dyskinesia from occurring in the early stages; this can happen from the individual having an increased dose of an antipsychotic drug. Often the symptoms of tardive dyskinesia are not apparent until the individual comes off of the antipsychotic drugs; however, when tardive dyskinesia worsens, the signs become visible.
Other dopamine antagonists and antiemetics can cause tardive dyskinesia, such as metoclopramide and promethazine, used to treat gastrointestinal disorders. Atypical antipsychotics are considered lower-risk for causing TD than their typical counterparts, with incidence rates of 13.1% and 32.4% respectively in short-term trials primarily utilising haloperidol as the typical antipsychotic. Quetiapine and clozapine are considered the lowest risk agents for precipitating TD. From 2008, there have been reported cases of the anti-psychotic medication aripiprazole, a partial agonist at D2 receptors, leading to tardive dyskinesia. As of 2013, reports of tardive dyskinesia in aripiprazole have grown in number. The available research seems to suggest that the concurrent prophylactic use of an antipsychotic and an antiparkinsonian drug is useless to avoid early extrapyramidal side-effects and may render the person more sensitive to tardive dyskinesia. Since 1973 the use of these drugs has been found to be associated with the development of tardive dyskinesia.
Risk factors
Tardive dyskinesia
An increased risk of tardive dyskinesia has been associated with smoking in some studies, although a negative study does exist. There seems to be a cigarette smoke-exposure-dependent risk for TD in people who are antipsychotic-treated. Elderly people are also at a heightened risk for developing TD, as are females and those with organic brain injuries or diabetes mellitus and those with the negative symptoms of schizophrenia. TD is also more common in those that experience acute neurological side effects from antipsychotic drug treatment. Racial discrepancies in TD rate also exist, with Africans and African Americans having higher rates of TD after exposure to antipsychotics. Certain genetic risk factors for TD have been identified including polymorphisms in the genes encoding the D3, 5-HT2A and 5-HT2C receptors.
Diagnosis
Tardive dyskinesia
Diagnosis is most commonly done by observing the patient's face. The criteria in which a diagnosis is made is usually followed in a step by step process.
Prevention
Tardive dyskinesia
Prevention of tardive dyskinesia is achieved by using the lowest effective dose of an antipsychotic for the shortest time. However, with diseases of chronic psychosis such as schizophrenia, this strategy must be balanced with the fact that increased dosages of antipsychotics are more beneficial in preventing recurrence of psychosis. If tardive dyskinesia is diagnosed, the causative drug should be discontinued. Tardive dyskinesia may persist after withdrawal of the drug for months, years or even permanently. Some studies suggest that practitioners should consider using atypical antipsychotics as a substitute to typical antipsychotics for people requiring medication. These agents are associated with fewer neuromotor side effects and a lower risk of developing tardive dyskinesia.
Studies have tested the use of melatonin, high dosage vitamins, and different antioxidants in concurrence with antipsychotic drugs (often used to treat schizophrenia) as a way of preventing and treating tardive dyskinesia. Although further research is needed, studies reported a much lower percentage of individuals developing tardive dyskinesia than the current rate of people for those taking antipsychotic drugs. Tentative evidence supports the use of vitamin E for prevention.
Treatment
Tardive dyskinesia
Valbenazine was approved by the FDA for tardive dyskinesia in April 2017. Tetrabenazine, which is a dopamine depleting drug, is sometimes used to treat tardive dyskinesia and other movement disorders (e.g. Huntington's chorea). Deutetrabenazine, an isotopic isomer of tetrabenazine, was approved by the FDA for tardive dyskinesia in August 2017. Vitamin B6 has been reported to be an effective treatment for TD in two randomised double-blind placebo-controlled trials, but the overall evidence for its effectiveness is considered "weak." Clonidine may also be useful in the treatment of TD, although dose-limiting hypotension and sedation may hinder its usage. Botox injections are used for minor focal dystonia, but not in more advanced tardive dyskinesia. As of 2018, evidence is insufficient to support the use of benzodiazepines, baclofen, progabide, sodium valproate, gaboxadol, or calcium channel blockers (e.g. diltiazem).
Epidemiology
Tardive dyskinesia
Tardive dyskinesia most commonly occurs in people with psychiatric conditions who are treated with antipsychotic medications for many years. The average rate of people affected has been estimated to be around 30% for individuals taking antipsychotic medication, such as that used to treat schizophrenia. A study being conducted at the Yale University School of Medicine has estimated that "32% of people develop persistent tics after 5 years on major tranquilizers, 57% by 15 years, and 68% by 25 years." More drastic data was found during a longitudinal study conducted on individuals 45 years of age and older who were taking antipsychotic drugs. According to this research study, 26% of people developed tardive dyskinesia after just one year on the medication. Another 60% of this at-risk group developed the disorder after 3 years, and 23% developed severe cases of tardive dyskinesia within 3 years. According to these estimates, the majority of people will eventually develop the disorder if they remain on the drugs long enough.
Elderly people are more prone to develop tardive dyskinesia, and elderly women are more at-risk than elderly men. The risk is much lower for younger men and women, and also more equal across the sexes. Several studies have recently been conducted comparing the number of people affected of tardive dyskinesia with second generation, or more modern, antipsychotic drugs to that of first generation drugs. The newer antipsychotics appear to have a substantially reduced potential for causing tardive dyskinesia. However, some studies express concern that the number of people affected has decreased far less than expected, cautioning against the overestimation of the safety of modern antipsychotics.
A practitioner can evaluate and diagnose a person with tardive dyskinesia by conducting a systematic examination. The practitioner should ask the person to relax, and look for symptoms like facial grimacing, eye or lip movements, tics, respiratory irregularities, and tongue movements. In some cases, people experience nutritional problems, so a practitioner can also look for a gain or loss in weight.
Apart from the underlying psychiatric disorder, tardive dyskinesia may lead to the social isolation of people with the condition. It also increases the risk of body dysmorphic disorder (BDD) and can even lead to suicide. Emotional or physical stress can increase the severity of dyskinetic movements, whereas relaxation and sedation have the opposite effect.
In popular culture
Tardive dyskinesia
In the TV series The Good Wife and The Good Fight, Michael J. Fox, who has Parkinson's disease, plays the lawyer Louis Canning, who has tardive dyskinesia.